Enhanced features for a great comfort and experience
Smaller and more flexible sensor: 80% reduction in size compared to the former Enlite Sensor
The New Generation Enlite sensor features an innovation to the sensor adhesive patch to help reduce skin irritations
More reliable sensor to transmitter connection, which can reduce the likelihood of data gaps. In the event of a lost connection between the sensor and the transmitter, the new Guardian 2 Link transmitter can store up to 10 hours of data
Insertion is easy
One button insertion process
Hidden needle during insertion
90 degree insertion angle
85% of patients agreed that insertion with Enlite was pain free**
Find out more about the New Generation Enlite insertionin this video.
CGM REDUCES HbA1c AND IMPROVES GLYCAEMIC CONTROL
Several randomised controlled trials1,4,5 showed that CGM can lead to:
Up to 1% HbA1c reduction without increasing the rate of severe hypoglycaemia
Tighter glycaemic control
Greater number of patients reaching the HbA1c target recommended by the American Diabetes Association (ADA)
All of these benefits can help you to achieve better control of your diabetes.
-New Generation Enlite™ sensor is indicated for adults and children and only intended for use with Medtronic products: MiniMed® 640G System, MiniMed® Paradigm® Veo™ System, MiniMed® Paradigm® REAL-Time System, Guardian® REAL-Time CGM System, iPro™2.
-New Generation Enlite™ sensor is not intended for use with Medtronic CGMS Gold® and iPro™.
-The Guardian™ 2 Link Transmitter is compatible with the MiniMed® 640G insulin pump, while the MiniLink™ Transmitter is compatible with the MiniMed® Paradigm® Veo™ System and the Guardian® REAL-Time CGM System.
*The dynamic suspend feature is based on certain criteria: sensor glucose must be within 70 mg/dL (3.9 mmol/L) of the low limit and predicted to be 20 mg/dL (1.1 mmol/L) above the low limit within 30 minutes AND the pump must not be in the refractory period.
4Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-1476.
5Raccah D, Sulmont V, Resnik Y,et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend Study. Diabetes Care. 2009;32(12):2245-2250.